The Evidence

Dysautonomia, POTS and MCS: is the autonomic nervous system part of this?

Different triggers, possible shared machinery. POTS is not proof that MCS is real, and MCS is not a form of POTS: POTS usually begins after an infection or another major physiological stressor, and MCS, by definition, centers on reactions to chemical exposures. What makes the pair worth a page is what happens after onset, where a subset of people with MCS show measurable abnormalities in some of the same nerve, autonomic and vascular systems that POTS disturbs.

Autonomic involvement is a serious MCS research lead, but MCS is not established as POTS and POTS is not established as the explanation for MCS. Small physiological studies show autonomic differences in some patients, while a large population study found no robust resting-autonomic signature. If you have MCS and also get a racing heart, dizziness or symptoms that worsen on standing, asking whether a separately diagnosable autonomic disorder such as POTS is present is medically worthwhile, and many clinicians will not test for it unless asked. A home pulse reading is a reason to ask a doctor, not a diagnosis.

Autonomic dysregulation is a real line of investigation in MCS, and it is not the leading mechanism here. Receptor sensitization is, because it has been tested by provocation in living patients and autonomic involvement has not.

Why the autonomic nervous system belongs in the MCS discussion

The autonomic nervous system regulates functions we do not consciously command: heart rate, vascular tone, sweating, digestion, pupil size, temperature regulation and aspects of breathing. Many symptoms reported during MCS reactions - racing heart, sweating changes, nausea, bowel changes, temperature intolerance, dizziness and post-exposure exhaustion - are therefore autonomic in character.

That makes dysautonomia a logical research target. It does not mean every person with MCS has POTS, and it does not mean POTS is the cause of MCS. The evidence instead suggests that autonomic dysregulation may be present in at least some MCS phenotypes.

What POTS is, and what is actually known about it

POTS is postural orthostatic tachycardia syndrome: a sustained heart-rate rise on standing without a fall in blood pressure, with symptoms of orthostatic intolerance for three months or more. It is well defined and it is measurable.

POTS is diagnosed on a measurement. The consensus definition is a sustained heart-rate increase of at least 30 beats per minute within ten minutes of standing or head-up tilt (40 for ages 12 to 19), without orthostatic hypotension, with symptoms of orthostatic intolerance lasting at least three months.10,12

The POTS literature gives this page a solid anchor because it has done the mechanism work MCS research has not yet done. Three principal physiological patterns are described: partial autonomic neuropathy, low effective circulating blood volume, and a hyperadrenergic state with excessive sympathetic activity. They frequently overlap in the same patient, and the hyperadrenergic state is most often secondary to one of the other two rather than a separate disease.11,12 POTS commonly develops after an infection, surgery, pregnancy or another major physiological stressor.11

Where POTS and MCS become more interesting: after onset

The two pathways do not begin in the same place. They may cross in the middle, in the machinery that regulates small sensory nerves, autonomic tone, sympathetic activation and vascular control.

POTS and MCS do not appear to have the same typical starting point. POTS commonly develops after an infection or another major physiological stressor. MCS, by definition, centers on symptoms associated with chemical exposures, often after an initiating exposure or a period of repeated exposures. That difference matters. Current evidence does not justify saying that MCS and POTS are the same illness or that they usually have the same cause, and this page does not use POTS as proof that MCS is real; MCS is real on its own evidence.

The more interesting overlap appears after the illnesses have developed. POTS involves measurable abnormalities in autonomic and cardiovascular regulation, described above. MCS research has also found evidence pointing toward nervous-system and autonomic involvement, although that evidence is much less complete. Three findings carry this section, each stated with its limitation.

The skin-biopsy cohort: an objective abnormality in a selected MCS group

One study examined 21 people previously diagnosed with MCS who had been referred for chronic pain and suspected small-fiber neuropathy. Skin biopsies demonstrated somatic small-fiber neuropathy in all 21. Eighteen reported autonomic symptoms. The autonomic nerve fibers examined in the same biopsies were normal.8

State the limitation exactly: these were 21 MCS patients referred because of chronic pain and suspected neuropathy, not 21 randomly selected people with MCS, and the authors themselves say more data are needed. And on a page about autonomic overlap, this study is not evidence of autonomic overlap. The symptom pattern was autonomic; the tissue finding was somatic, and the autonomic innervation was spared. The page treats it as an objective tissue abnormality in a selected MCS group, consistent with the site’s small-fiber page, which calls these findings interesting and not a biomarker. It does not show that autonomic neuropathy causes MCS. It cannot be dismissed either: an objective abnormality was present in every patient in this group, on a stain that cannot be talked into a result.

The standing study: an autonomic signal that is not POTS

Seventeen women with MCS were measured by impedance cardiography sitting and immediately on standing. Heart rate rose, stroke volume fell, diastolic pressure and vascular resistance rose. That is the normal pattern, and the authors report that the size of the changes was considerably smaller than previously observed in healthy participants.4

This is a small descriptive study with no control group of its own, and it is included because of what it does not show: this MCS group did not produce a POTS-type response. It produced a blunted one. If autonomic regulation is involved in MCS, this study suggests it may not be involved in the same direction as POTS, which is exactly the kind of difference this page is about.

A 2025 review places autonomic dysfunction among the shared features under investigation

A 2025 narrative review of MCS, ME/CFS and fibromyalgia describes autonomic dysfunction among the neurophysiological abnormalities observed across environmental-sensitivity illnesses, while stating that the underlying mechanisms remain under investigation.9 A narrative review generates hypotheses; it does not establish a shared mechanism, and it is not a second measurement. It is cited here for the observation, not for a conclusion.

The most defensible picture

POTS runs from a physiological stressor to autonomic and vascular dysregulation to orthostatic intolerance. MCS runs from an exposure to still-unresolved sensory, neurological and immune changes to multisystem reactions. Different starts; possible shared middle.

POTS

  • infection or other physiological stressor
  • autonomic and vascular dysregulation
  • blood pooling, impaired volume regulation, sympathetic compensation
  • orthostatic intolerance and tachycardia

MCS

  • chemical exposure and/or another initiating event
  • still-unresolved sensory, neurological, immune and physiological changes
  • abnormal responses to previously tolerated low-level exposures
  • multisystem MCS symptoms

The two pathways do not clearly begin in the same place. They may cross somewhere in the middle. That intersection may involve small sensory nerve fibers, autonomic regulation, sympathetic activation, vascular control, immune signaling, or interactions among several of these systems.

That is not proof that POTS causes MCS, that MCS causes POTS, or that chemical exposure commonly causes POTS. It is something more useful scientifically: two different illnesses may disturb some of the same regulatory machinery. Understanding that shared machinery could explain why some people with chemical sensitivity also experience a racing heart, dizziness, temperature intolerance, sweating abnormalities, exercise intolerance, gastrointestinal disturbance, blood-pressure changes, or symptoms that become markedly worse on standing. For those patients, asking whether a separately diagnosable autonomic disorder such as POTS is also present is medically worthwhile.

What has been measured

A 17-woman hemodynamic study is too small to define an MCS-specific autonomic signature, but it shows that autonomic regulation is measurable rather than purely subjective. Using impedance cardiography, investigators found significant changes in heart rate, stroke volume, left-ventricular ejection time, diastolic pressure, and systemic vascular resistance during standing.4 The pattern was the normal one; the size of the changes was considerably smaller than previously observed in healthy participants, which is to say this group did not produce a POTS-type response. It produced a blunted one.

Another real-world study monitored eight MCS patients for 24 hours with simultaneous volatile-organic-compound monitoring and Holter heart-rate-variability recording.5 Some participants showed relationships among VOC changes, reduced parasympathetic activity and subjective symptoms. Again, the sample was tiny and patterns were not uniform, but the design is valuable because it linked environmental measurement, physiology and symptoms in real time rather than relying only on retrospective recall.

A large newer study provides an important restraint

A population-based Danish analysis, published in 2024, included 143 people categorized with MCS and more than 5,500 comparison participants.7 Resting heart rate was slightly higher in the MCS group, but the association disappeared after adjustment for chronic stress, and the investigators found no meaningful association between MCS and standard resting heart-rate-variability measures.

That negative result matters. It tells us not to turn "autonomic symptoms" into "universal autonomic dysfunction" or to treat resting HRV as an established MCS biomarker. Autonomic abnormalities may be episodic, trigger-dependent, orthostatic, subgroup-specific or simply not captured well by short resting HRV measurements.

Where POTS fits

A person can have MCS without POTS, POTS without MCS, or both. POTS is a defined orthostatic syndrome with a measurement behind it; that is what makes the overlap worth measuring rather than assuming.

POTS is a defined orthostatic syndrome, not a synonym for dysautonomia and not a synonym for MCS. A person can have MCS without POTS, POTS without MCS, or both. Because POTS can involve tachycardia, dizziness, fatigue, cognitive difficulty, gastrointestinal symptoms, temperature intolerance and abnormal vascular regulation, the overlap is clinically and biologically worth measuring.

The research question is not "Is MCS actually POTS?" It is whether a subset of people with consensus-defined MCS has reproducible orthostatic or autonomic abnormalities, whether that subgroup has different triggers or recovery patterns, and whether autonomic normalization accompanies regained chemical tolerance.

Could someone with MCS also have undiagnosed POTS?

Yes, and it is testable. If standing reliably brings on a racing heart, lightheadedness, shakiness or a need to sit within minutes, the question is worth putting to a doctor, because POTS has a measurement and MCS does not.

The pattern to notice is orthostatic: symptoms that appear or worsen on standing and ease on lying down. A racing or pounding heart within minutes of standing, lightheadedness, visual dimming, tremulousness, brain fog that clears when seated, nausea and exercise intolerance are the common ones.12

The test that defines POTS is a ten-minute standing test or head-up tilt with continuous heart-rate and blood-pressure recording, looking for the sustained rise of 30 beats per minute or more without a fall in blood pressure.10,13 The test is what decides it; a home pulse reading is a reason to ask a doctor, not a diagnosis.

An autonomic specialist is appropriate when the standing test is positive or equivocal, when symptoms are disabling, or when a primary-care clinician is unsure how to proceed. Cardiology, neurology and dedicated autonomic clinics all see POTS; the 2015 consensus statement and the 2019 NIH expert statement are the documents a clinician will recognize.12,13

What this page does not say: that everyone with MCS has dysautonomia. Most people with MCS have never been measured, the one small standing study of MCS patients found a blunted response rather than a POTS response, and the large Danish study found no resting signature. The point is that POTS is one of the few overlapping conditions that can actually be tested for, and treated on its own evidence if found.

What the registry is answering

The Canary Registry records clinician-diagnosed POTS or other dysautonomia separately from MCS, the test used where known, orthostatic symptoms, measured heart-rate changes when available, blood-pressure instability, abnormal sweating, heat and cold intolerance, bowel and bladder changes, exercise intolerance, post-exposure heart-rate changes, and whether these symptoms began before, with or after chemical sensitivity and relative to any infection.

That chronology can then guide targeted testing: standing tests or tilt-table testing, continuous heart-rate and blood-pressure monitoring, sudomotor testing, pupillometry and exposure-linked physiological monitoring. It lets us ask whether measured POTS marks out an MCS subgroup with a different onset story, different triggers, a different course, or a different response to exposure reduction; and the reverse, whether people whose POTS came first later developed chemical intolerance, which would say something about the direction of travel. The goal is to identify subgroups rather than force one autonomic model onto everyone.

Where we stand

Different triggers, possible shared machinery. POTS and MCS are not the same illness and do not usually share a cause; POTS starts with a physiological stressor and MCS starts with an exposure. After onset, a subset of people with MCS show objective abnormalities in small sensory nerves and in autonomic regulation, and POTS is the best-defined disorder of that same regulatory system. The best larger resting study did not find a robust general MCS signal, so dysautonomia and POTS are overlap phenotypes to investigate, not labels to place on MCS as a whole. That makes POTS a measurement worth taking in a person with MCS who has orthostatic symptoms, and it makes the shared machinery a research question the registry is built to answer; the most informative future studies will measure autonomic function during orthostatic stress and real environmental triggers, not only at quiet rest. It does not make POTS an explanation for MCS, and this page will not be quoted as if it did.

We followed the evidence. Here’s where it leads →

Sources

Sources

1Skovbjerg S, Hauge CR, Rasmussen A, Winkel P, Elberling J. Mindfulness-based cognitive therapy to treat multiple chemical sensitivities: a randomized pilot trial. Scandinavian Journal of Psychology. 2012. PMID: 22530938.
2Rossi S, Pitidis A. Multiple Chemical Sensitivity: Review of the State of the Art in Epidemiology, Diagnosis, and Future Perspectives. Journal of Occupational and Environmental Medicine. 2017;60(2):138-146. PMID: 29111991. DOI: 10.1097/JOM.0000000000001215.
3Molot J, Sears M, Anisman H. Multiple chemical sensitivity: It's time to catch up to the science. Neuroscience & Biobehavioral Reviews. 2023;151:105227. DOI: 10.1016/j.neubiorev.2023.105227.
4McFetridge-Durdle JA, Routledge FS, Sampalli T, Fox R, Livingston H, Adams B. Hemodynamic response to postural shift in women with multiple chemical sensitivities. Biological Research for Nursing. 2009;10(3):267–273. PMID: 19017670. DOI: 10.1177/1099800408324251.
5Mizukoshi A, Kumagai K, Yamamoto N, et al. In-situ Real-Time Monitoring of Volatile Organic Compound Exposure and Heart Rate Variability for Patients with Multiple Chemical Sensitivity. International Journal of Environmental Research and Public Health. 2015;12(10):12446–12465. PMID: 26445055. DOI: 10.3390/ijerph121012446.
6Dantoft TM, Elberling J, Brix S, Szecsi PB, Vesterhauge S, Skovbjerg S. An elevated pro-inflammatory cytokine profile in multiple chemical sensitivity. Psychoneuroendocrinology. 2014;40:140-150.
7Bjerregaard AA, Brinth L, Petersen MW, et al. Heart rate variability is not associated with multiple chemical sensitivity in a cross-sectional population-based study – The Danish study of functional disorders. Journal of Psychosomatic Research. 2025;188:111992. PMID: 39579587. DOI: 10.1016/j.jpsychores.2024.111992.
8Fileccia E, Incensi A, Ventruto F, et al. Small Fiber Neuropathy in Patients With Chronic Pain and a Previous Diagnosis of Multiple Chemical Sensitivity Syndrome. Journal of Neuropathology & Experimental Neurology. 2021;80(9):868–874. PMID: 34402516. DOI: 10.1093/jnen/nlab082.
9Watai K, et al. The Gut-Brain-Immune Axis in Environmental Sensitivity Illnesses: Microbiome-Centered Narrative Review of Fibromyalgia Syndrome, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, and Multiple Chemical Sensitivity. International Journal of Molecular Sciences. 2025;26(20). PMID: 41155291. DOI: 10.3390/ijms26209997.
10Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clinical Autonomic Research. 2011;21(2):69–72. PMID: 21431947. DOI: 10.1007/s10286-011-0119-5.
11Raj SR. Postural tachycardia syndrome (POTS). Circulation. 2013;127(23):2336–2342. PMID: 23753844. DOI: 10.1161/CIRCULATIONAHA.112.144501.
12Vernino S, Bourne KM, Stiles LE, et al. Postural orthostatic tachycardia syndrome (POTS): State of the science and clinical care from a 2019 National Institutes of Health Expert Consensus Meeting – Part 1. Autonomic Neuroscience. 2021;235:102828. PMID: 34144933. DOI: 10.1016/j.autneu.2021.102828.
13Sheldon RS, Grubb BP, Olshansky B, et al. 2015 Heart Rhythm Society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope. Heart Rhythm. 2015;12(6):e41–e63. PMID: 25980576. DOI: 10.1016/j.hrthm.2015.03.029.
← Back to MCSDisability.com
↑